Important: Models were tasked with extracting evidence from documents. Some outputs may be low quality and should be scored accordingly.
Your task: Compare the model-generated prediction (right panel) against the ground truth criteria (left panel).
Evaluation scale (0-4):
Consider both content accuracy and completeness. Some predictions may be technically "correct" but incomplete or out of order.
INCLUSION CRITERIA 1. Eligible to receive ocrelizumab per the United States Package Insert (USPI) 2. Able to comply with the study protocol, in the investigator's judgment 3. Age 18-55 years, inclusive 4. Have a diagnosis of PPMS or RMS, confirmed per the revised 2017 Mc 5. Donald criteria 6. Expanded Disability Status Scale (EDSS) score of 0 to 6.5, inclusive 7. For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of <1% per year during the treatment period and for at least 6 months after the last dose of study treatment (per the USPI) EXCLUSION CRITERIA 1. Experienced serious IRR(s) 2. History of life-threatening infusion reaction to ocrelizumab 3. Known presence of other neurological disorders 4. Pregnancy or lactation, or intention to become pregnant during the study 5. Any concomitant disease that may require chronic treatment with systemic corticosteroids or immunosuppressants during the course of the study 6. Significant, uncontrolled disease, such as cardiovascular (including cardiac arrhythmia), pulmonary (including obstructive pulmonary disease), renal, hepatic, endocrine, and gastrointestinal or any other significant disease that may preclude patient from participating in the study 7. Congestive heart failure 8. Known active bacterial, viral, fungal, mycobacterial infection or other infection or any severe episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks prior to baseline visit or oral antibiotics within 2 weeks prior to baseline visit 9. History of or currently active primary or secondary immunodeficiency 10. History or known presence of recurrent or chronic infection (e.g., HIV, syphilis, tuberculosis) 11. History of recurrent aspiration pneumonia requiring antibiotic therapy 12. History of malignancy, including solid tumors and hematological malignancies,except basal cell, in situ squamous cell carcinoma of the skin, and in situ carcinoma of the cervix of the uterus that have been excised with clear margins 13. History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies 14. History of alcohol or drug abuse within 24 weeks prior to enrollment 15. Receipt of a live vaccine within 6 weeks prior to enrollment 16. Systemic corticosteroid therapy within 4 weeks prior to enrollment 17. Contraindications to or intolerance of oral or IV corticosteroids, including IV methylprednisolone (or equivalent steroid) administered according to the country label 18. Treatment with alemtuzumab 19. Treatment with a B-cell targeted therapies other than ocrelizumab 20. Treatment with a drug that is experimental 21. Abnormal laboratory results per local laboratory standards and investigator assessment
Modified Eligibility Criteria for Version 1 of the Ocrelizumab Study Protocol Based on the provided text, here are the modified eligibility criteria for the Ocrelizumab study protocol, Version 1, incorporating the evidence from the document: INCLUSION CRITERIA 1. Age: 18-55 years, inclusive 2. Diagnosis: PPMS or RMS, confirmed per the revised 2017 McDonald criteria (Thompson et al. 2017) 3. EDSS Score: 0 to 6.5, inclusive 4. Childbearing Potential: 5. Women of childbearing potential must agree to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of <1% per year during the treatment period and for at least 6 months after the last dose of study treatment (per the USPI). 6. Contraceptive methods include: 7. Bilateral tubal ligation 8. Male sterilization 9. Established hormonal contraceptives that inhibit ovulation 10. Hormone-releasing intrauterine devices 11. Copper intrauterine devices 12. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. 13. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception. 14. Eligible for Ocrelizumab: Able to comply with the study protocol, in the investigator's judgment. EXCLUSION CRITERIA 1. Experienced serious IRR(s) 2. History of other neurological disorders that may interfere with the study 3. History of severe allergic reactions to humanized or murine monoclonal antibodies 4. Pregnancy or lactation 5. Current or recent use of systemic corticosteroids or other immunosuppressants 6. Known or suspected active infection requiring hospitalization or treatment with IV antibiotics within 4 weeks prior to baseline visit 7. History of or current malignancy, including solid tumors and hematological malignancies, except for basal cell, in situ squamous cell carcinoma of the skin, and in situ carcinoma of the cervix of the uterus that have been excised with clear margins 8. History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies 9. History of alcohol or drug abuse within 24 weeks prior to enrollment 10. Receipt of a live vaccine within 6 weeks prior to enrollment 11. Systemic corticosteroid therapy within 4 weeks prior to enrollment 12. Treatment with alemtuzumab 13. Treatment with a B-cell targeted therapy other than ocrelizumab 14. History of recurrent or chronic infection (e.g., HIV, syphilis, tuberculosis) 15. History of severe autoimmune disorders that may interfere with the study 16. History of severe heart failure 17. History of pulmonary disease, including obstructive pulmonary disease 18. History of renal disease, including renal failure 19. History of hepatic disease, including liver failure 20. History of endocrine disorders, including thyroid disease 21. History of gastrointestinal disorders, including gastrointestinal bleeding 22. History of cardiovascular disease, including arrhythmia 23. History of gastrointestinal disorders, including gastrointestinal bleeding 24. History of hematologic disorders, including anemia 25. History of metabolic disorders, including diabetes mellitus 26. History of psychiatric disorders, including psychosis 27. History of other medical conditions that may interfere with the study 28. Important Notes: 29. This is a summary of the modified eligibility criteria based on the provided text. 30. The full protocol should be consulted for a complete and accurate understanding of the eligibility criteria. 31. The specific inclusion and EXCLUSION CRITERIA 1. may be subject to change based on the evolving understanding of the disease and the study design. 2. It is crucial to consult with the study team and the relevant regulatory authorities for any specific questions or clarifications.